Parker Robert B, Yates C Ryan, Soberman Judith E, Laizure S Casey
Department of Pharmacy, University of Tennessee Health Science Center, Memphis 38163, USA.
Pharmacotherapy. 2003 Aug;23(8):979-87. doi: 10.1592/phco.23.8.979.32881.
To determine the effects of grapefruit juice on the pharmacokinetics of oral digoxin, a P-glycoprotein substrate not metabolized by cytochrome P450 3A4, in healthy volunteers, and to assess whether polymorphic multidrug-resistance-1 (MDR1) expression contributes to interindividual variability in digoxin disposition.
Prospective, open-label, unblinded, crossover study.
University research center.
Seven healthy adult volunteers (four men, three women).
Each subject received a single oral dose of digoxin 1.0 mg with water or grapefruit juice with at least a 2-week washout between treatments. During the grapefruit juice phase, juice was administered 3 times/day for 5 days before digoxin administration to maximize any effect on P-glycoprotein.
Digoxin pharmacokinetics in the presence and absence of grapefruit juice were compared. The MDR1 exon 26 C3435T genotype was determined by real-time polymerase chain reaction. Compared with water, grapefruit juice significantly reduced the digoxin absorption rate constant (3.0 +/- 2.4 to 1.2 +/- 1.0 hr(-1), p<0.05) and increased absorption lag time (0.32 +/- 0.12 to 0.53 +/- 0.34 hr, p<0.05). Grapefruit juice did not affect digoxin maximum concentration (Cmax), area under the curve (AUC), elimination half-life, or renal clearance. The effect of grapefruit juice on digoxin Cmax (-45% to +41%) and AUC(0-4) (-29% to +25%) varied substantially among subjects and was inversely correlated with the values during the water phase. Trends toward higher digoxin Cmax AUC, and absorption rate constant during the water phase were found in CC homozygotes compared with subjects carrying a T allele.
Inhibition of intestinal P-glycoprotein does not appear to play an important role in drug interactions involving grapefruit juice. Interindividual variability in response to grapefruit juice may be related to the balance of intestinal drug uptake and efflux transport.
确定葡萄柚汁对健康志愿者口服地高辛(一种非细胞色素P450 3A4代谢的P-糖蛋白底物)药代动力学的影响,并评估多药耐药-1(MDR1)基因多态性表达是否对地高辛处置的个体间差异有影响。
前瞻性、开放标签、非盲交叉研究。
大学研究中心。
7名健康成年志愿者(4名男性,3名女性)。
每位受试者接受单次口服1.0 mg地高辛,分别用水或葡萄柚汁送服,两次治疗之间至少有2周的洗脱期。在葡萄柚汁阶段,在服用地高辛前5天,每天3次给予葡萄柚汁,以最大化对P-糖蛋白的任何影响。
比较了存在和不存在葡萄柚汁时地高辛的药代动力学。通过实时聚合酶链反应确定MDR1外显子26 C3435T基因型。与水相比,葡萄柚汁显著降低了地高辛的吸收速率常数(从3.0±2.4降至1.2±1.0 hr⁻¹,p<0.05),并延长了吸收延迟时间(从0.32±0.12增至0.53±0.34小时,p<0.05)。葡萄柚汁对地高辛的最大浓度(Cmax)、曲线下面积(AUC)、消除半衰期或肾清除率无影响。葡萄柚汁对地高辛Cmax(-45%至+41%)和AUC(0 - 4)(-29%至+25%)的影响在受试者之间差异很大,并且与水相期间的值呈负相关。与携带T等位基因的受试者相比,CC纯合子在水相期间地高辛Cmax、AUC和吸收速率常数有升高趋势。
肠道P-糖蛋白的抑制似乎在涉及葡萄柚汁的药物相互作用中不起重要作用。对葡萄柚汁反应的个体间差异可能与肠道药物摄取和外排转运的平衡有关。